Unilever Eyes Up to $4 Billion Acquisition of Thorne as Haleon Competes in Bidding
0xBroomberg
Unilever is competing to acquire U.S. supplement brand Thorne at a valuation of up to $4 billion, with Haleon bidding in parallel — the latest move in Unilever's pivot from food to health, though a rich price tag and a stretched balance sheet raise real integration risk.
What is the deal on the table?
Private-equity firm L Catterton has put Thorne up for sale. Both Unilever and consumer-health company Haleon have submitted bids, at a valuation of up to $4 billion.
The process is still early-stage. No final decision has been made; Unilever and L Catterton declined to comment.
This means → neither price nor buyer is locked in, but two major bidders chasing the same asset signals that premium supplement brands are now fiercely contested.
Why is Thorne worth $4 billion?
Founded in 1984, Thorne sells magnesium, omega-3, and other dietary supplements. It is rated the top clinically recommended brand by healthcare practitioners — the key differentiator from mass-market rivals.
Revenue grew from $229 million in 2022 to over $500 million in 2025 and is projected to reach $650 million in 2026 — nearly tripling in three years.
L Catterton took Thorne private in August 2023 for $680 million. A $4 billion exit would deliver roughly a 5× return in about three years.
In plain terms = Thorne is not an influencer-driven supplement. It is built on physician endorsement and fast growth — which is how a PE firm can flip the price fivefold in three years.
Why does Unilever want a supplement company?
CEO Fernando Fernandez is driving a strategic pivot: exit food, bet on beauty and health.
In April 2026 Unilever paid roughly $1.2 billion for gummy-supplement brand Grüns. Earlier acquisitions include Liquid IV, Nutrafol, Olly Nutrition, and SmartyPants; the health category posted double-digit sales growth in 2025.
Thorne's "clinical-grade professional" positioning complements the existing mass-market lineup — one targets doctors and premium consumers, the other serves the general market.
This means → Unilever is not just buying brands. It is assembling a full health-brand matrix from mass to professional.
Is the price tag too high?
$4 billion against Thorne's projected 2026 revenue of $650 million works out to roughly 6.2× price-to-sales.
For comparison, the April Grüns deal priced at about 4× sales — Thorne carries a premium of more than 50%.
That premium reflects Thorne's brand moat in professional medical channels, but it also means Unilever needs Thorne to keep growing fast just to justify the price.
How big is the integration risk?
Unilever's M&A track record has clear blemishes: it bought subscription razor brand Dollar Shave Club for $1 billion in 2016, failed to integrate it, and sold in 2023. Graze ran persistent operating losses under Unilever ownership.
Thorne CEO Colin Watts notes that millennials and Gen Z now outspend baby boomers on health, and Thorne is a prime beneficiary of that generational shift — but whether that growth momentum survives inside a large conglomerate is the central question.
This reflects a deeper tension: Unilever just merged its food business into McCormick, and its stock fell 7% on the day of disclosure as investors flagged concerns about debt levels. Another $4 billion deal would further test the balance sheet's capacity.
Content is for reference only, not financial advice.